Ok yeah that rings a bell, though that is for cell based next gen flu vaccines and is not related to Covid 19. Its also not going to be operational until 2026. What matters with Covid 19 is how much it can sell a dose for, less how much it has to pay AstraZ for the rights to do that and other costs. Its also completley unknown how long the vaccines work for and the extent to which Covid19 will mutate in the future. So it could be a new business line, but its not a CSL owned product and numerous other vaccines are likely to exist.
Ann: Half Year Results Announcement, page-57
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$311.12 |
Change
3.100(1.01%) |
Mkt cap ! $150.3B | |||
| Open | High | Low | Value | Volume |
| $308.75 | $311.12 | $306.32 | $220.9M | 712.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $310.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $311.13 | 1131 | 2 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |